Precision ATG with or without verapamil in new-onset T1D
What this study tests
A University of Florida phase 2 trial testing low-dose ATG against placebo in newly diagnosed T1D, stratifying participants by an ex vivo immune-responder signature so that predicted responders and non-responders are balanced across the arms, with a second-year re-randomisation to open-label verapamil. About 60 participants aged 6-35 at two US sites.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2025-11-26.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- See registry for full inclusion/exclusion criteria. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted yet.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- AUC C-peptide between ATG and placebo values
- Change in 2-hr MMTT AUC C-peptide
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]